000294079 001__ 294079
000294079 005__ 20241205145456.0
000294079 0247_ $$2doi$$a10.1039/D4TB01831A
000294079 0247_ $$2pmid$$apmid:39420720
000294079 0247_ $$2ISSN$$a2050-750X
000294079 0247_ $$2ISSN$$a2050-7518
000294079 037__ $$aDKFZ-2024-02100
000294079 041__ $$aEnglish
000294079 082__ $$a610
000294079 1001_ $$aChen, Bo$$b0
000294079 245__ $$aRadiation-activated PD-L1 aptamer-functionalized nanoradiosensitizer to potentiate antitumor immunity in combined radioimmunotherapy and photothermal therapy.
000294079 260__ $$aLondon ˜[u.a.]œ$$bRSC$$c2024
000294079 3367_ $$2DRIVER$$aarticle
000294079 3367_ $$2DataCite$$aOutput Types/Journal article
000294079 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1733406830_12320
000294079 3367_ $$2BibTeX$$aARTICLE
000294079 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294079 3367_ $$00$$2EndNote$$aJournal Article
000294079 500__ $$a2024 Dec 4;12(47):12220-12231
000294079 520__ $$aReactive oxygen species (ROS)-mediated immunogenic cell death (ICD) is crucial in radioimmunotherapy by boosting innate antitumor immunity. However, the hypoxic tumor microenvironment (TME) often impedes ROS production, limiting the efficacy of radiotherapy. To tackle this challenge, a combination therapy involving radiotherapy and immune checkpoint blockade (ICB) with anti-programmed death-ligand 1 (PD-L1) has been explored to enhance antitumor effects and reprogram the immunosuppressive TME. Here, we introduce a novel PD-L1 aptamer-functionalized nanoradiosensitizer designed to augment radiotherapy by increasing X-ray deposition specifically at the tumor site. This innovative X-ray-activated nanoradiosensitizer, comprising gold-MnO2 nanoflowers, efficiently enhances ROS generation under single low-dose radiation and repolarizes M2-like macrophages, thereby boosting antitumor immunity. Additionally, the ICB inhibitor BMS-202 synergizes with the PD-L1 aptamer-assisted nanoradiosensitizer to block the PD-L1 receptor, promoting T cell activation. Furthermore, this nanoradiosensitizer exhibits exceptional photothermal conversion efficiency, amplifying the ICD effect. The PD-L1-targeted nanoradiosensitizer effectively inhibits primary tumor growth and eliminates distant tumors, underscoring the potential of this strategy in optimizing both radioimmunotherapy and photothermal therapy.
000294079 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000294079 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294079 7001_ $$aHe, Yinbo$$b1
000294079 7001_ $$aBai, Long$$b2
000294079 7001_ $$aPan, Shulin$$b3
000294079 7001_ $$aWang, Yinggang$$b4
000294079 7001_ $$aMu, Min$$b5
000294079 7001_ $$aFan, Rangrang$$b6
000294079 7001_ $$00000-0002-6509-0313$$aHan, Bo$$b7
000294079 7001_ $$0P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aHuber, Peter$$b8$$udkfz
000294079 7001_ $$aZou, Bingwen$$b9
000294079 7001_ $$00000-0002-4440-6366$$aGuo, Gang$$b10
000294079 773__ $$0PERI:(DE-600)2702241-9$$a10.1039/D4TB01831A$$gp. 10.1039.D4TB01831A$$n47$$p12220-12231$$tJournal of materials chemistry / B$$v12$$x2050-750X$$y2024
000294079 909CO $$ooai:inrepo02.dkfz.de:294079$$pVDB
000294079 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000294079 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000294079 9141_ $$y2024
000294079 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2023-10-26$$wger
000294079 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ MATER CHEM B : 2022$$d2023-10-26
000294079 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000294079 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000294079 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000294079 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000294079 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000294079 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000294079 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ MATER CHEM B : 2022$$d2023-10-26
000294079 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000294079 980__ $$ajournal
000294079 980__ $$aVDB
000294079 980__ $$aI:(DE-He78)E055-20160331
000294079 980__ $$aUNRESTRICTED